Cargando…

The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma

OBJECTIVE: To study and analyze the clinical efficacy of axitinib combined with tislelizumab in the treatment of advanced renal cell carcinoma and its effects on renal function and serum cytokines. METHODS: Totally 49 patients with advanced renal cancer treated in our hospital from November 2018 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhixin, Chen, Jiaqi, Li, Qianyu, Li, Na, Yu, Jing, Liu, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970885/
https://www.ncbi.nlm.nih.gov/pubmed/35368892
http://dx.doi.org/10.1155/2022/2700166
_version_ 1784679530411065344
author Wang, Zhixin
Chen, Jiaqi
Li, Qianyu
Li, Na
Yu, Jing
Liu, Feng
author_facet Wang, Zhixin
Chen, Jiaqi
Li, Qianyu
Li, Na
Yu, Jing
Liu, Feng
author_sort Wang, Zhixin
collection PubMed
description OBJECTIVE: To study and analyze the clinical efficacy of axitinib combined with tislelizumab in the treatment of advanced renal cell carcinoma and its effects on renal function and serum cytokines. METHODS: Totally 49 patients with advanced renal cancer treated in our hospital from November 2018 to January 2020 were randomized to treatment with axitinib (control group, n = 27) or axitinib combined with tislelizumab (study group, n = 22). The clinical efficacy, renal function and adverse reactions were compared between the two groups. RESULTS: After treatment, both groups showed a significant decrease in blood urea nitrogen (BUN) and serum creatinine (SCR), but treatment with axitinib plus tislelizumab led to a significantly greater reduction than did the axitinib (each p < 0.05). After treatment, both groups showed a significant decrease in TNF-β1, VEGF, TIMP-1, and MMP-2, but treatment with axitinib plus tislelizumab led to a significantly greater reduction than did the axitinib (each p < 0.05). The study group had significantly higher rates of adverse reactions (p < 0.05). Significant difference was observed in ORR (59.1% vs 40.7%) and DCR (81.8% vs 66.7%) between the study group and the control group, with higher results in study group (p < 0.05). The study group was superior to the control group in OS (p < 0.05). CONCLUSION: Our study presents an effective alternative for advanced renal cell carcinoma by using axitinib plus tislelizumab. Limitations merit attention, and the study group had higher rates of adverse reactions. Therefore, further studies are suggested to secure a larger population of subjects.
format Online
Article
Text
id pubmed-8970885
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-89708852022-04-01 The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma Wang, Zhixin Chen, Jiaqi Li, Qianyu Li, Na Yu, Jing Liu, Feng J Oncol Research Article OBJECTIVE: To study and analyze the clinical efficacy of axitinib combined with tislelizumab in the treatment of advanced renal cell carcinoma and its effects on renal function and serum cytokines. METHODS: Totally 49 patients with advanced renal cancer treated in our hospital from November 2018 to January 2020 were randomized to treatment with axitinib (control group, n = 27) or axitinib combined with tislelizumab (study group, n = 22). The clinical efficacy, renal function and adverse reactions were compared between the two groups. RESULTS: After treatment, both groups showed a significant decrease in blood urea nitrogen (BUN) and serum creatinine (SCR), but treatment with axitinib plus tislelizumab led to a significantly greater reduction than did the axitinib (each p < 0.05). After treatment, both groups showed a significant decrease in TNF-β1, VEGF, TIMP-1, and MMP-2, but treatment with axitinib plus tislelizumab led to a significantly greater reduction than did the axitinib (each p < 0.05). The study group had significantly higher rates of adverse reactions (p < 0.05). Significant difference was observed in ORR (59.1% vs 40.7%) and DCR (81.8% vs 66.7%) between the study group and the control group, with higher results in study group (p < 0.05). The study group was superior to the control group in OS (p < 0.05). CONCLUSION: Our study presents an effective alternative for advanced renal cell carcinoma by using axitinib plus tislelizumab. Limitations merit attention, and the study group had higher rates of adverse reactions. Therefore, further studies are suggested to secure a larger population of subjects. Hindawi 2022-03-24 /pmc/articles/PMC8970885/ /pubmed/35368892 http://dx.doi.org/10.1155/2022/2700166 Text en Copyright © 2022 Zhixin Wang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wang, Zhixin
Chen, Jiaqi
Li, Qianyu
Li, Na
Yu, Jing
Liu, Feng
The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
title The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
title_full The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
title_fullStr The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
title_full_unstemmed The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
title_short The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
title_sort effects of axitinib plus tislelizumab in the treatment of advanced renal cell carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970885/
https://www.ncbi.nlm.nih.gov/pubmed/35368892
http://dx.doi.org/10.1155/2022/2700166
work_keys_str_mv AT wangzhixin theeffectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma
AT chenjiaqi theeffectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma
AT liqianyu theeffectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma
AT lina theeffectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma
AT yujing theeffectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma
AT liufeng theeffectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma
AT wangzhixin effectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma
AT chenjiaqi effectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma
AT liqianyu effectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma
AT lina effectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma
AT yujing effectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma
AT liufeng effectsofaxitinibplustislelizumabinthetreatmentofadvancedrenalcellcarcinoma